CNEY Receives NASDAQ Minimum Bid Price Requirement Extension
LISHUI, China, Dec. 4, 2024 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY" or the "Company") today announced that on November 26, 2024, the Company received a written notice from the Listing Qualifications Staff of The Nasdaq Stock...
Appian Unveils Latest Platform Release for Better Process and Better Outcomes
New enhancements scale high-volume workflows and increase efficiency and analysis with AI MCLEAN, Va., Dec. 3, 2024 /PRNewswire/ -- Appian (Nasdaq: APPN) today announced its latest platform release, which delivers process automation powered by...
Half of Australians live with chronic health conditions, over a third forced to leave their jobs as a result
Patient advocates call for more support for Australian workers living with a chronic condition/s following the release of a new insights report SYDNEY, Dec. 4, 2024 /PRNewswire/ -- A new report released today has found that of the one in two...
Asia's Transformative Era: Unveiling the "Asian Dream" through New Study "Truth About Ascending Asia"
SINGAPORE, Dec. 4, 2024 /PRNewswire/ -- McCann Worldgroup has launched its latest insights study, the Truth about Ascending Asia, at an event held at Singapore's Asian Civilisations Museum. Over 70 clients, partners and media joined the advertising...
China Clean Expo 2025, Taking Your Cleaning Business to a New Height!
SHANGHAI, Dec. 4, 2024 /PRNewswire/ -- 26th China Clean Expo (CCE), organized by IM Sinoexpo and supported by ISSA – The worldwide cleaning industry association, will take place at Shanghai New International Expo Center (SNIEC) from March 31st to...
Hublot celebrates the 25th Anniversary of OpusX with a special edition Classic Fusion Chronograph
CLASSIC FUSION CHRONOGRAPH ARTURO FUENTE KING GOLD To stay up-to-date, follow: @Hublot #Hublot SANTIAGO DE LOS CABALLEROS, Dominican Republic, Dec. 4, 2024 /PRNewswire/ -- A shared drive towards uncompromising excellence and a passion for enjoying...
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery Statistically and clinically...
Biogénesis Bagó opens offices in Vietnam, strengthening its presence in Asia
After years of commitment to animal health in the Asian market providing high-quality biotechnological solutions, this significant milestone further strengthens the company's long-term expansion strategy in the region. This is also reinforced by the...